CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Gensight Biologics SA is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Gensight Biologics SA
74 Rue du Faubourg Saint-Antoine
Phone: +33 176217220p:+33 176217220 PARIS, 75012  France Ticker: SIGHTSIGHT
Business Summary
Gensight Biologics SA is a France-based company. The Company focuses on the development and commercialization of gene therapies for retinal neurodegenerative diseases and selected central nervous system disorders. It operates as a clinical-stage biopharmaceutical business specializing in innovative gene therapy platforms designed to preserve or restore vision in patients affected by severe ophthalmic conditions. Its activities are centered on two core technology platforms: Mitochondrial Targeting Sequence (MTS), which is used to address diseases linked to mitochondrial dysfunction, and optogenetics, which is intended to restore light sensitivity in retinal cells. It develops therapeutic candidates for inherited and acquired retinal disorders, including products designed for single-administration treatment through intravitreal injection. It conducts research, clinical development, and related commercialization activities in ophthalmology and neurodegenerative disease applications.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202612/31/2025YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Michael S.Wyzga 71 1/1/2024 10/1/2013
Chief Executive Officer, Director LaurenceRodriguez 58 1/1/2025 1/1/2025
Chief Financial Officer Jan E.Umiastowski 9/16/2024 9/16/2024
9 additional Officers and Directors records available in full report.

Business Names
Business Name
GNST
SIGHT

General Information
Number of Employees: 18 (As of 6/30/2026)
Outstanding Shares: 234,518,122 (As of 6/30/2026)
Stock Exchange: EPA
Federal Tax Id: 807511647


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, November 14, 2026